HDL abnormalities in type 2 diabetes: Clinical implications

Area of Science:

• Endocrinology and Metabolism
• Cardiovascular Research
• Lipidology

Background:

• Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality in Type 2 Diabetes Mellitus (T2DM).
• High-Density Lipoprotein (HDL) particles in T2DM patients are characterized by altered number, composition, and function, leading to reduced anti-atherosclerotic properties despite normal HDL cholesterol (HDL-C) levels.
• Hyperglycemia exacerbates HDL abnormalities, decreasing lipid and protein concentrations within HDL particles.

Purpose of the Study:

• To review the impact of hyperglycemia on HDL particle characteristics in T2DM.
• To evaluate the efficacy of current and emerging therapeutic strategies targeting HDL metabolism for cardiovascular risk reduction in T2DM.
• To underscore the importance of HDL metabolism as a research area for understanding and treating diabetes-associated complications.

Main Methods:

• Review of existing literature on HDL metabolism, T2DM, and cardiovascular disease.
• Analysis of pharmacological interventions targeting hyperglycemia and their effects on HDL.
• Evaluation of clinical trial outcomes and preclinical findings for novel HDL-modulating agents.

Main Results:

• Standard hyperglycemic treatments and medications like metformin show inconsistent effects on HDL-C and function.
• Pharmacological elevation of HDL-C has not translated to clinical benefits in reducing ASCVD risk.
• Lowering Low Density Lipoprotein cholesterol (LDL-C) with statins and ezetimibe is effective in T2DM patients; novel HDL-targeting agents show promise but require further large-scale trials.

Conclusions:

• HDL particle dysfunction is a significant contributor to ASCVD in T2DM, independent of HDL-C levels.
• Current therapeutic approaches have limitations in addressing HDL abnormalities; focus is shifting towards HDL particle function and metabolism.
• Further research into HDL metabolism is essential for developing effective treatments for diabetes-related cardiovascular complications.